I stumbled across this today even though it’s a week old. Spherix announced that it’s Phase 3 product, D-Tagatose, “has been selected as one of the top 10 most promising cardiovascular/metabolic therapies in development,” according to a business analyst group assembled by Windhover Information. Spherix plans to announce the Phase 3 results in the next few weeks, and according to the article, “to date, there do not appear to be any significant safety concerns in the Phase 3 trial.”

Windhover Information Names D-Tagatose One of Top 10 Most Promising CV/Metabolic Drugs in Development